Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
1(100.0%)
1Total
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07305480Active Not Recruiting

Longitudinal Clinical Observation of a Digital Twin Model for Blastocyst Evaluation in IVF Clinics

Role: lead

NCT04675970Completed

Long Term Follow up Patients With Premature Ovarian Failure ex Vivo Gene Therapy

Role: lead

NCT05080465Phase 3Completed

Long Term Follow up Mesenchymal Stem Cell Therapy for Patients Virus-related Liver Cirrhosis

Role: lead

NCT04642911Active Not Recruiting

Longterm Follow-up of Subjects With Diabetes 2 Type Treatment With ex Vivo Gene Therapy

Role: lead

All 4 trials loaded